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       Colorectal cancer is the second leading cause of cancer-related death in US (1). Most of 
the mortality reflects local, regional and distant metastatic tumors. Cancers that are confined 
within the wall of the colon are often curable with surgery while tumor cells that have spread 
into other organs like liver and lung has low curable possibility, even though the 
chemotherapies and monoclonal antibodies can extend the person's life and improve quality 
of life(2, 3).  Surgery is the main treatment for primary colorectal tumors but recurrence can 
happen and develop into metastasis. In addition, colorectal cancer has been proved resistant 
to chemotherapy although little success has been achieved using a combination of 5-
fluorouracil and levamisole. Survival rate decreases from 90% for primary tumors to 10% for 
distal metastasis of colorectal cancer (1). More attention has been attracted to 
immunotherapy against metastatic colon cancer, because of its potential for higher specificity 
and less side effect(4). Our main aim is to increase the eradication of metastatic colorectal 
cancer cells by optimizing immunotherapeutic approaches that have been well-underway.  
Guanylyl cyclase C (GCC) is a mucosal antigen expressed on apical surface of intestinal 
epithelial cells. It is a potential target for colorectal cancer immunotherapeutic approaches, 
because of its expression on >95% of colorectal cancer cells and their maintenance through 
all the stages of colorectal cancer (5-9).This is because GCC is mainly expressed in the 
intestine so that its expression can be utilized to detect metastasis of colon cancer. The aim of 
this project is to develop an immunotherapy based on GCC-specific TCR transduced CD8 T 
cells to attack metastatic cancer cells. The initial step of this project is cloning out CD8 TCR 
specific to GCC. This can be done by T-hybridoma technology by which we fused T cells 
from mice immunized by GCC vaccine with fusion partner cells (BWZ/CD8)(10). 
 
Background: Colorectal cancer is the fourth most commonly diagnosed cancer in the world 
in   the US and the 2nd leading cause of cancer-related deaths in US (1). For primary tumors, 
it is highly curable. This type of cancer occurs when abnormal cells grow in the lining of the 
large intestine (colon) or rectum. Although there are treatment options such as surgery, 
radiation, chemical and biological therapies, all treatments present a risk of side effects. 
Patients in their early state may achieve a cure; however surgery removes the bulk of the 
tumor leaving behind microscopic residual disease, which ultimately results in 
recrudescence. Although current radiotherapeutic agents and chemotherapeutic agents and 
biological toxins are potent cytotoxins, they do not discriminate between normal cells and 
malignant cells, producing adverse effects and dose limiting toxicity. 
    Guanylyl cyclase C, a member of guanylyl cyclase family of receptors, is the receptor for 
two endogenous ligands guanylin and uroguanylin and for the exogenous ligand heat-stable 
enterotoxin, ST. ST is produced by enterotoxigenic bacteria causing the infectious 
diarrhea(11). 
 As a mucosa-specific protein, which is restricted in intestine, GCC can be utilized to detect 
metastases(12). Moreover, its mucosa-restricted expression makes it ideally suited as a novel 
target antigen for the immunotherapy of colorectal cancer. In Waldman lab, a recombinant 
adenovirus vaccine expressing GCC (Ad5-GCC) has been generated and tested in mice. 
Vaccination of mice with Ad5-GCC showed decent immunological responses(7). 
Specifically, vaccination produced GCC-specific CD8+ T cell responses, but failed to 
generate GCC-specific antibodies or GCC-specific CD4+ T cell responses(6). Our main aim 
is to utilize GCC-specific cytotoxic T cell response toward metastatic colorectal cancer using 
adoptive T cell therapy. T cells are a group of lymphocytes that are highly effective in the 
cell-mediated immunity, because of a special receptor on surface called T cell receptors. By 
nature, a T cell receptor is very specific to a certain antigen, providing exquisite targeting 
ability. T cells are activated by binding of their cell receptors to a complex of a peptide and 
major histocompatibility molecules expressed on the surface of antigen presenting cells. 
When T cell receptors are engaged, signals are transmitted into nucleus and then T cells 
become activated. After T cells are activated, they express activation markers, produce 
immune factors, proliferate, recognize and kill target cells. However, the low frequency of 
  
GCC-specific CD8 T cells largely limits the tumor eradication. To overcome the limitation, 
we would transduce GCC-specific TCR gene into activated T cells to increase the frequency 
of GCC-specific T cells in the entire population. Therefore, the first step of this project is to 
clone out the GCC-specific TCR. 
 The process of identifying GCC-specific TCR was done by using T hybridoma technology 
to make hybrid cell lines (called hybridomas) by fusing T cells that have been exposed to an 
antigen with fusion partner cells which are thymomas caused by irradiation. For biological 
studies, T-cell hybridomas have several advantages over normal T cells and T-cell lines. T-
cell hybridomas grow rapidly in tissue culture. Their proliferation does not require 
stimulations because they divide spontaneously. Normal resting T cells do not divide in 
culture and must be freshly isolated from animals immediately before use. Splenocytes can 
divide in vitro, however they require stimulation in the form of antigen and antigen 
presenting cells and/or cytokines such as interleukin 2 (IL-2). 
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  The results of selecting GCC-specific T hybridoma are usually tested by using an assay 
called MUG assay. MUG assay is a sensitive fluorescence assay in which activated T hybridoma 
can express β-galactosidase. In the presence of β-galactosidase, the colorless 4-
methylumbelliferyl β-D-galactopyranoside (MUG) substrate is hydrolyzed into a product that 
has a bright blue fluorescence. Fluorescence can then be detected at Excitation/Emission = 
360/460 nm. Thymoma/fusion partner cells have been engineered to have β-Galactosidase 
genes with no TCR expression on surface. However,β-Galactosidase expression requires 
thymoma/hybridoma activation. T cells have T cell receptors but no β-Galactosidase genes. When 
they fuse into T-hybridoma, this T-hybridoma has both T cell receptors and β-Galactosidase genes. If 
they are stimulated with GCC epitope (GCC254-262) and they also can express the β-Galactosidase, 
then they are GCC-specific T hybridoma.(5) 
The main aim of such a process (T cell hybridoma technology) in this experiment is to clone 
out GCC-specific T cell receptors and transduce normal T cells with this T cell receptor then 
introduced it back into the mice system to target cancer. This process is known as adoptive T 
cell therapy. Adoptive T cell therapy involves the isolation and ex vivo expansion of tumor 
specific T cells to achieve greater number of T cells than what could be obtained by 
vaccination alone.  The tumor-specific T cells are then injected into patients with cancer in an 
attempt to give their immune system the ability to overwhelm remaining tumor with T cells, 
which can attack cancer cells. 
 
 
 
 
 
 
Aim: Cloning of GCC-specific T cell Receptor 
 
Procedure:  
1. BALB/c mice were immunized with recombinant GCC-expressing viral vectors 
(GCC-Ad). 
2. At day 14, the time of the optimal immune response, the spleens are harvested and the 
splenocytes are then isolated. Lysis buffer is used to kill all the red blood cells thus 
leaving only the white blood lymphocytes. 
3. Once the splenocytes are isolated, they are then fused with the immortalized 
thymoma/fusion partner cells in a 1:1 ratio and then placed in 96-well plates to grow. 
The rest of the splenocytes are then placed into three flasks for 1, 2 and 3weeks of 
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stimulation respectively using rhIL-2 and GCC peptide for more T hybridoma 
fusions. Antigen presenting cells are added periodically as well, this is to increase the 
frequency of GCC specific T cells for further fusions by T cell proliferation. The 
fusion is accomplished by using polyethylene glycol (PEG).   
4. Hypoxanthine aminopterin thymidine medium is then added 1 day and 1 week after 
fusion. Aminopterin blocks the de novo pathway that allows for nucleotide synthesis. 
Hence, unfused thymoma cells die, as they cannot produce nucleotides by the de 
novo or salvage pathways because their HGPRT gene (hypoxanthine-guanine 
phosphoribosyltransferase) is mutated. However, T-hybridoma can produce HGPRT 
by genes from T cells and survive the HAT selection. Removal of the unfused 
thymoma cells is necessary because they have the potential to outgrow other cells, 
especially weakly established hybridomas by competing for resources from medium. 
Unfused T cells die as they have a short life span without stimulation. In this way, 
only the T cell hybridomas survive. 
5. At day 12, 96-well plates are then screened for growing T-hybridomas using a 
microscope. Growing T-hybridomas are identified by the presence of cell colonies. 
6. Growing T hybridomas are then transferred to 24-well plates to allow further growth 
for 5 days. MUG assay is then done to test for selecting GCC- specific T cells. 
  
 
 
 
 
Results: 
 
Graph #1 showing results obtained where DMSO (blue) was used as the control and 
GCC252-264 peptide (red) was used to stimulate GCC-specific T hybridoma. The 
results show that growing T-hybridomas were none that were GCC-specific. In order to 
identify GCC-specific T-hybridomas, the GCC peptide (blue) must have at least 10000 
points increase compared to the control (DMSO) in fluorescence reading; however the 
results show that there was no difference. 
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Summary and Future Directions: 
      T hybridoma technology is an effective way to identify antigen specific T cell 
receptors (TCRs). In order to increase the chance of amplifying the frequency of antigen-
specific T cells, we have to make them proliferate by stimulating them with antigen. 
However, in order to increase the fusion efficiency for tests, critical measures have to be 
revised: During the fusion reaction, maintaining the temperature at 37°C is very 
important for the membrane events that occur during and immediately after the PEG 
mediated fusion event.  A major limitation is because of the small volume, the cells can 
rapidly come down to room temperature. In addition, the thymoma/fusion partner cells 
could also be tested using super antigens to see if they are still potent for the method. 
   Future directions for this project are: To clone out the T-cell receptor of GCC-specific 
CD8 T cells and test their affinity.  In addition, we also want to give the mice colon 
cancer cell lines-CT26 modified to express GCC and then treat them with GCC-specific 
TCR transduced CD8 T cells. 
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